MedPath

Improving Disease Severity

Not Applicable
Active, not recruiting
Conditions
Psoriasis
Alopecia Areata
Polymorphous Light Eruption
Interventions
Other: Lumiton yarn shirt
Other: Lumiton yarn sleeve
Other: Lumiton yarn hat
Registration Number
NCT05391178
Lead Sponsor
Wake Forest University Health Sciences
Brief Summary

Phototherapy, including ultraviolet B (UVB) and ultraviolet A (UVA) light, has been used to treat a number of dermatologic conditions. Psoriasis is one of the most common conditions treated with phototherapy, in which phototherapy is often indicated for extensive disease with contraindications for other systemic treatments. The mechanism of action of phototherapy for the treatment of psoriasis is not completely understood; however, it is known that UVB light induces apoptosis of pathogenic T cells and keratinocytes, which may reduce the overactive immune response and epidermal hyperproliferation. Phototherapy has shown some efficacy for other diseases, such as alopecia areata (AA) and polymorphous light eruption (PMLE). However, phototherapy is not always an accessible treatment option for patients due to cost or lack of time.

Detailed Description

Recent advancements in nanotechnology have led to the development of medical devices (lasers and LED devices) with unique phototherapy properties that emit radiation in the infrared wavelengths, allowing patients to benefit from the effects of phototherapy treatment in a more convenient way. Preclinical studies demonstrated the positive effects of infrared radiation exposure on the skin including, increased collagen synthesis and expression of transforming growth factor-beta1 (TGF-beta1). Other studies suggested possible antimicrobial effects from infrared radiation, with decreased colonization of Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae on the skin after exposure. Compared to other fabric technology, such as Far-Infrared (FIR) fabric technology that reflects body heat, fabric made from Lumiton yarn converts external light in the UV and visible spectrum and emits light in the red and near-infrared spectrum for the body. Lumiton yarn absorbs energy from 350 nm to 600 nm (the light spectrum from UV to visible red light) and emit energy from 600 to 1000 nm (red, near-infrared spectrum). The Lumiton yarn contains red/NIR light-emitting dyes. The effectiveness of the technology is proportional to the intensity of the light, with its peak effectiveness under sunlight.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
13
Inclusion Criteria
  • Adult participants ≥18 years of age
  • Participants who live in the US,
  • Participants who are diagnosed with mild-to-severe AA, PMLE, or psoriasis
  • Participants have sufficient command of the English language
Exclusion Criteria
  • Participants less than the age of 18
  • Participants who do not live in the US
  • Participants who are not diagnosed with mild to severe AA, PMLE, or psoriasis
  • Participants without a sufficient command of the English language
  • Participants with concurrent medical conditions that are at risk of confounding the study outcomes
  • Participants currently using concomitant phototherapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Polymorphous Light EruptionLumiton yarn shirtPolymorphous light eruption participants will be provided a shirt made from the Lumiton yarn. The participants will be instructed to wear the shirt made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
PsoriasisLumiton yarn sleevePsoriasis participants will be provided sleeves made from the Lumiton yarn to cover their arms. The participants will be instructed to wear the sleeves made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
Alopecia AreataLumiton yarn hatAlopecia areata participants will be provided a hat made from the Lumiton yarn. The participants will be instructed to wear the hat made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
Primary Outcome Measures
NameTimeMethod
Disease severity - PASIWeek 12

Psoriasis Area and Severity Index-75 (PASI-75%) scores The percentage area affected by psoriasis is evaluated in the four regions of the body. In each region, the area is expressed as nil (0), 1-9% (score 1), 10-29% (score 2), 30-49% (score 3), 50-69% (score 4), 70-89% (score 5) or 90-100% (score 6).

Disease severity - photoWeek 12

Lesion photos

Disease severity - SALTWeek 12

Severity of Alopecia Tool (SALT) score The SALT score is computed by measuring the percentage of hair loss in each of 4 areas of the scalp-vertex (40%), right profile (18%), left profile (18%), and posterior (24%)-and adding the total to achieve a composite score.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Wake Forest University Health Sciences, Dermatology

🇺🇸

Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath